GASTRIC-CANCER AND PREMALIGNANT LESIONS IN ATROPHIC GASTRITIS - A CONTROLLED TRIAL ON THE EFFECT OF SUPPLEMENTATION WITH ALPHA-TOCOPHEROL AND BETA-CAROTENE

Citation
K. Varis et al., GASTRIC-CANCER AND PREMALIGNANT LESIONS IN ATROPHIC GASTRITIS - A CONTROLLED TRIAL ON THE EFFECT OF SUPPLEMENTATION WITH ALPHA-TOCOPHEROL AND BETA-CAROTENE, Scandinavian journal of gastroenterology, 33(3), 1998, pp. 294-300
Citations number
29
Categorie Soggetti
Gastroenterology & Hepatology
ISSN journal
00365521
Volume
33
Issue
3
Year of publication
1998
Pages
294 - 300
Database
ISI
SICI code
0036-5521(1998)33:3<294:GAPLIA>2.0.ZU;2-M
Abstract
Background: Vitamin E and beta-carotene are considered to decrease the risk of gastric cancer both in humans and in laboratory animals. We s tudied the effect of dietary supplementation with alpha-tocopherol and beta-carotene on the end-of-trial prevalence of premalignant and mali gnant lesions of the stomach in older men with atrophic gastritis. Met hods: The study was carried out within the Alpha-Tocopherol, Beta-Caro tene Cancer Prevention Study (ATBC study) in Finland, in which 29,133 male smokers aged 50-69 years were randomly assigned to receive daily 50 mg alpha-tocopherol, 20 mg beta-carotene, both of these agents, or placebo, for 5-8 years. Serum pepsinogen was determined at base line a nd after 3 years' supplementation to find men with atrophic gastritis. A low serum pepsinogen I level, indicating atrophic gastritis of the the corpus area of the stomach, was found in 2132 men. These men were invited to have upper gastrointestinal endoscopy (gastroscopy), which was performed on 1344 subjects after a median supplementation time of 5.1 years. Results: Neoplastic alterations were found in 63 of the men (4.7%): 42 with definite dysplasias of low grade (moderate dysplasia) , 7 with definite dysplasias of high grade (severe dysplasia), 11 with carcinomas (of which 7 were 'early' cancers), and 3 with carcinoid tu mors. Neither alpha-tocopherol (relative risk, 0.98; 95% confidence in terval, 0.57-1.69) nor beta-carotene (relative risk, 1.13; 95% confide nce interval, 0.65-1.95) supplementation had any association with end- of-trial prevalence of gastric neoplasias after adjustment for other p ossible risk factors. The effect was not modified by base-line serum l evel or dietary intake of vitamins, prevalence of Helicobacter pylori infection, or other covariates. Conclusions: We thus conclude that sup plementation with alpha-tocopherol or beta-carotene for 5 years has no major impact on the occurrence of neoplastic changes of the stomach i n older male smokers with atrophic gastritis.